Researchers test if electronic health records can mimic Gold-Standard cancer studies
NCT ID NCT07485166
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether information from electronic health records can be used to recreate the results of two earlier clinical trials (CheckMate 017 and 057) for advanced lung cancer. Researchers will compare survival outcomes in patients who started either nivolumab or docetaxel, using data from over 800 patients. The goal is not to find a new treatment, but to see if real-world data can reliably answer clinical questions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could show that real-world data can reliably replace some traditional trials, speeding up research and lowering costs.
- What could go wrong
- This is an observational study, not a new treatment test. Results may not match the original trials due to data quality or hidden biases.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED NON-SMALL CELL SQUAMOUS LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Brigham and Women's Hospital
Somerville, Massachusetts, 02145, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill combo outperform standard therapy for a Hard-to-Treat lung cancer?
- Seeing Cancer's hidden markers: a new PET tracer could reveal who responds to targeted therapy
- Could a gentler chemo combo with delayed immunotherapy tame advanced lung cancer?
- Herbal mix and cancer drug join forces to fight fluid in lungs
- New drug HDM2020 targets tough lung cancer in early trial
- Can a lighter chemo punch still knock out lung cancer when paired with immunotherapy?